5 results
The primary objective of this study is to test the hypothesis that treatment with LY3074828 is superior to placebo in inducing clinical remission at Week 12 in subjects with moderate to severe ulcerative colitis (UC).The secondary objectives are:-To…
To test the hypothesis that mirikizumab is superior to placebo in inducing clinical remission at Week 12 in patients with moderately to severely active ulcerative colitis (UC)
To attenuate the impact and duration of delayed graft funtion by dampening schemia reperfusion injury
To study the potential renoprotective effects of supplementation of alkaline phosphatase in hospitalized patients with AKI
To test the hypothesis that mirikizumab is superior to placebo in maintaining clinical remission at Week 40 (Week 52 of continuous therapy) among patients induced into clinical remission with mirikizumab